DxPx U.S., presented by Brown Gibbons Lang
& Company, is an industry + investor partnering conference
dedicated to Diagnostics, Digital Health, Precision Medicine, and
Life Sciences Tools
CHICAGO, June 17,
2024 /PRNewswire/ -- The field of diagnostics is
rapidly evolving, driven by advancements in technology that are
revolutionizing disease detection and management. Ahead of DxPx
U.S., the industry + investor partnering conference dedicated to
Diagnostics, Digital Health, Precision Medicine, and Life Sciences
Tools, five key trends are emerging that are set to define the
future of the industry.
These trends, along with other key topics in diagnostics, will
be highlighted at DxPx U.S., which takes place from July 30th to August 1st in Chicago, Illinois within the exposition hall
of ADLM 2024 (formerly the AACC Annual Scientific Meeting
& Clinical Lab Expo), the premier global laboratory medicine
meeting.
Five key trends in the Diagnostics space:
- The groundbreaking potential of spatial biology: As the
healthcare landscape continues to evolve, spatial biology is
emerging as a promising platform that will have a transformative
impact on cancer diagnosis, prognosis, and treatment selection. How
far away are we from clinical use?
- Breakthrough designation and automated reimbursement:
Medical device makers may find it easier to secure health insurance
reimbursement for their products with the FDA breakthrough
designation. But what is the status of reimbursement for the FDA
breakthrough designation, and what impact could this have on
innovative technologies?
- Integration of artificial intelligence: A.I. has the
power to enhance the accuracy and efficiency of diagnostic
processes. What are the latest developments in machine learning
algorithms' ability to help analyze complex medical data, aid in
early disease detection, and provide more precise diagnostics
results?
- Advancements in liquid biopsy technology: Epigenetics is
showing promising results as the best pathway for detecting
early-stage cancers and other diseases. Is a non-invasive approach
using bodily fluids gaining momentum? How far are we away from
real-life implementation?
- Defining the "new normal" in diagnostics post COVID: Q1
earnings reports continue to reveal a trend of revenue decreases
for major diagnostics and tools companies, although they many are
still beating market expectations. The lingering question remains:
when can we expect to see an end to the impact of COVID-19 on these
companies' financial performance?
To read more about the discussions happening around these trends
at DxPx U.S. 2024, including more information on the expert
panelists being featured, visit:
https://dxpx-conference.com/us/agenda/.
To see if you're one of the startups, investors, or members of
the media eligible for a free or discounted registration, go to:
https://dxpx-conference.com/dxpx-us-2024-registration/.
BGL's Healthcare & Life Sciences team has decades of
experience advising companies across the diagnostics, research
tools, lab equipment, and device landscape. We have provided
capital formation, technology strategy, corporate ventures, and
medical device M&A strategy for a wide range of companies.
Additionally, we maintain active relationships with global industry
participants and capital providers, and closely follow regulatory
and reimbursement trends. Our sector involvement enables us to not
only provide unique access to capital providers, but also identify
and execute strategic opportunities for our investment banking
clients.
About Brown Gibbons Lang & Company
Brown
Gibbons Lang & Company (BGL) is a leading independent
investment bank and financial advisory firm focused on the global
middle market. The firm advises private and public corporations and
private equity groups on mergers and acquisitions, capital
markets, financial restructurings, business valuations
and opinions, and other strategic matters. BGL has
investment banking offices in Chicago, Cleveland, Los
Angeles, and New York, and
real estate offices in Chicago,
Cleveland, and San Antonio. The firm is also a founding
member of Global M&A Partners, enabling BGL to service clients
in more than 35 countries around the world. Securities transactions
are conducted through Brown, Gibbons, Lang & Company
Securities, LLC, an affiliate of Brown Gibbons Lang & Company
LLC and a registered broker-dealer and member of FINRA and
SIPC. For more information, please visit www.bglco.com.
![(PRNewsfoto/Brown Gibbons Lang & Company) (PRNewsfoto/Brown Gibbons Lang & Company)](https://mma.prnewswire.com/media/805620/BGL_Logo.jpg)
View original content to download
multimedia:https://www.prnewswire.com/news-releases/five-emerging-trends-to-watch-in-diagnostics-ahead-of-dxpx-us-2024-302174720.html
SOURCE Brown Gibbons Lang & Company